RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors

Cancer Discovery

Volumn 5, Issue 12, 2015, Pages 1262-1270

  Cheng, Haiying ^a   Zou, Yiyu ^a   Ross, Jeffrey S ^b   Wang, Kai ^b   Liu, Xuewen ^c,d   Halmos, Balazs ^a,c   Ali, Siraj M ^b   Liu, Huijie ^a   Verma, Amit ^a   Montagna, Cristina ^a   Chachoua, Abraham ^e   Goel, Sanjay ^a   Schwartz, Edward L ^a   Zhu, Changcheng ^f   Shan, Jidong ^a   Yu, Yiting ^a   Gritsman, Kira ^a   Yelensky, Roman ^b   Lipson, Doron ^b   Otto, Geoff ^b   Hawryluk, Matthew ^b   Stephens, Philip J ^b   Miller, Vincent A ^b   Piperdi, Bilal ^a   Perez Soler, Roman ^a   more..

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FOUNDATION MEDICINE   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; DURVALUMAB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PEMETREXED; SAPANISERTIB; TICILIMUMAB; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; RICTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ADULT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; GENE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG CANCER; LUNG RESECTION; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; RICTOR GENE; TISSUE MICROARRAY; TREATMENT RESPONSE; WESTERN BLOTTING; YOUNG ADULT; ADOLESCENT; AGE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG RESISTANCE; DRUG SCREENING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SILENCING; GENETIC VARIATION; GENETICS; IC50; LUNG NEOPLASMS; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ADOLESCENT; AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE KNOCKDOWN TECHNIQUES; GENETIC VARIATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MALE; MICE; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960131361     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0971     Document Type: Article

References (28)

1. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012; 18: 349-51
2. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument- Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-302
3. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012; 14: 129-38
4. Ali SM, Sabatini DM. Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J Biol Chem 2005; 280: 19445-8
5. Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle 2011; 10: 2305-16
6. Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, et al. mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. Cancer Res 2010; 70: 9360-70
7. Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 2009; 15: 7207-16
8. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009; 15: 148-59
9. Bashir T, Cloninger C, Artinian N, Anderson L, Bernath A, Holmes B, et al. Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLoS One 2012; 7: e47741
10. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-20
11. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-25
12. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signaling 2013; 6: pl1
13. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401–4
14. Kent C, Shih JCB, Reinert A, Jones S, Kelley RK, Infante J R, et al. Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers. J Clin Oncol 2012; 30: (suppl; abstr 3006).
15. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-31
16. Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003; 39: 55-61
17. Cheng H SM, Pendurti G, Liang Y, Piperdi B, Perez-Soler R. Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. Lung Cancer Manag 2014; 3: 67-75
18. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, et al. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/ mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer 2015;121:3481–90
19. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48
20. Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan C E, et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol 2014; 67: 772-6
21. Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, et al. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol 2014; 9: 1324-31
22. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010; 16: 5900-7
23. Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD, et al. Dual specificity phosphatase 6 (DUSP6) is an ETSregulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 2010; 31: 577-86
24. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 1988; 167: 1428-41
25. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1: 2315-9
26. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916–25
27. Downing TE, Oktay MH, Fazzari MJ, Montagna C. Prognostic and predictive value of 16p12.1 and 16q22.1 copy number changes in human breast cancer. Cancer Genet Cytogenet 2010; 198: 52-61
28. Cawthorne C, Swindell R, Stratford IJ, Dive C, Welman A. Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model. J Biomol Tech 2007; 18: 120-3.